Verona Pharma PLC Schedule 13G passive stakes

Pentwater Capital Management LP and Matthew Halbower have fully divested their 6.1% stake in Verona Pharma plc.

Perceptive Advisors and related entities have reported ceasing beneficial ownership of Verona Pharma plc shares following its acquisition by Merck & Co., Inc.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a beneficial ownership of 1.2% in Verona Pharma PLC's American Depositary Shares.

BlackRock Portfolio Management LLC has reported a 6.0% beneficial ownership stake in Verona Pharma PLC, holding 27,645,624 common shares.

RA Capital Management and related entities filed an amendment to their Schedule 13G, disclosing a 0.7% beneficial ownership stake in Verona Pharma plc.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a 6.4% beneficial ownership stake in Verona Pharma plc as of June 30, 2025.

Janus Henderson Group PLC has disclosed a 7.2% beneficial ownership stake in Verona Pharma PLC, holding over 6.1 million American Depositary Shares.

RA Capital Management and its affiliates have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 7.1% of Verona Pharma plc's Ordinary Shares as of March 31, 2025.

Janus Henderson Group PLC has filed a Schedule 13G, revealing a 6.5% beneficial ownership stake in Verona Pharma PLC's American Depositary Shares.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.9% in Verona Pharma plc as of December 31, 2024.

Maverick Capital, Ltd. and its affiliates have filed an amended Schedule 13G, disclosing a 3.8% beneficial ownership stake in Verona Pharma Plc as of December 31, 2024.